Wuhan YZY Biopharma Co., Ltd. (HKG:2496)
Hong Kong · Delayed Price · Currency is HKD 3.300
-0.300 (-8.33%)
Aug 24, 2026, 11:10 AM HKT
Wuhan YZY Biopharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 62.81 | 66.86 | 107.81 | - | - | - |
Other Revenue | - | - | - | - | 2.28 | 12.16 |
| 62.81 | 66.86 | 107.81 | - | 2.28 | 12.16 | |
Revenue Growth | -57.94% | -37.99% | - | - | -81.28% | - |
Cost of Revenue | 34.49 | 56.12 | 22.74 | - | - | - |
Gross Profit | 28.32 | 10.74 | 85.07 | - | 2.28 | 12.16 |
Selling, General & Admin | 24.13 | 22.81 | 26.59 | 22.31 | 20.53 | 31.5 |
Research & Development | 35.59 | 78.2 | 164.99 | 155.05 | 157.33 | 112.89 |
Other Operating Expenses | -9.71 | -9.71 | -8.53 | -11.97 | - | - |
Operating Expenses | 50.01 | 91.3 | 183.05 | 165.4 | 177.85 | 144.39 |
Operating Income | -21.69 | -80.56 | -97.98 | -165.4 | -175.58 | -132.23 |
Interest Expense | -4.65 | -4.95 | -4.08 | -2.39 | -2.47 | -14.97 |
Interest & Investment Income | 0.51 | 0.76 | 2.57 | 1.05 | 0.28 | 0.16 |
Currency Exchange Gain (Loss) | -1.46 | 0.07 | 1.95 | -1.92 | - | - |
Other Non Operating Income (Expenses) | -4.79 | -0.03 | - | -24.63 | -11.77 | -2.67 |
EBT Excluding Unusual Items | -32.07 | -84.72 | -97.54 | -193.29 | -189.53 | -149.71 |
Gain (Loss) on Sale of Investments | - | - | - | 1.61 | 0.67 | 1.26 |
Gain (Loss) on Sale of Assets | -0.09 | -0.02 | -0.07 | -0.02 | -0 | -0.55 |
Other Unusual Items | - | - | 0.01 | - | - | 0.47 |
Pretax Income | -32.16 | -84.73 | -97.6 | -191.7 | -188.87 | -148.52 |
Net Income | -32.16 | -84.73 | -97.6 | -191.7 | -188.87 | -148.52 |
Net Income to Common | -32.16 | -84.73 | -97.6 | -191.7 | -188.87 | -148.52 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 194 | 194 | 194 | 185 | 172 | 152 |
Shares Outstanding (Diluted) | 194 | 194 | 194 | 185 | 172 | 152 |
Shares Change | - | - | 4.72% | 7.60% | 13.10% | - |
EPS (Basic) | -0.17 | -0.44 | -0.50 | -1.04 | -1.10 | -0.98 |
EPS (Diluted) | -0.17 | -0.44 | -0.50 | -1.04 | -1.10 | -0.98 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -22.46 | -102.22 | -187.95 | -178.11 | -100.61 |
Free Cash Flow Per Share | - | -0.12 | -0.53 | -1.01 | -1.03 | -0.66 |
Gross Margin | 45.09% | 16.06% | 78.90% | - | 100.00% | 100.00% |
Operating Margin | -34.53% | -120.50% | -90.88% | - | -7710.89% | -1087.03% |
Profit Margin | -51.20% | -126.73% | -90.53% | - | -8294.51% | -1220.96% |
Free Cash Flow Margin | - | -33.60% | -94.81% | - | -7822.31% | -827.14% |
EBITDA | -18.07 | -76.76 | -92.01 | -158.99 | -169.23 | -125.2 |
EBITDA Margin | -28.77% | -114.81% | -85.34% | - | - | - |
D&A For EBITDA | 3.62 | 3.8 | 5.97 | 6.41 | 6.34 | 7.03 |
EBIT | -21.69 | -80.56 | -97.98 | -165.4 | -175.58 | -132.23 |
EBIT Margin | -34.53% | -120.50% | -90.88% | - | - | - |